Publication:
Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective.

dc.contributor.authorLópez-Méndez, Tania B
dc.contributor.authorSánchez-Álvarez, Miguel
dc.contributor.authorTrionfetti, Flavia
dc.contributor.authorPedraz, José L
dc.contributor.authorTripodi, Marco
dc.contributor.authorCordani, Marco
dc.contributor.authorStrippoli, Raffaele
dc.contributor.authorGonzález-Valdivieso, Juan
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderMinisterio de Universidades (España)es_ES
dc.date.accessioned2023-09-12T11:27:35Z
dc.date.available2023-09-12T11:27:35Z
dc.date.issued2023-03-04
dc.description.abstractIn recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipWork in the laboratories of the authors is funded by grants from the Italian Ministries for Health (Ricerca Corrente) to M.T., from Education, Univer‑ sity and Research (MIUR; 000003_17_MAP_STRIP and FISR 2020-Covid FISR2020IP_03366) to R.S; and from the Spanish Ministerio de Ciencia e Innovación (PID2021-128106NA-I00). M.C. is currently a recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innova‑ tion (RYC2021-031003-I) and was funded by “Maria Zambrano” contract from Spanish Ministry of Universities and Complutense University of Madrid. M.S-A is recipient of a Ramón y Cajal tenure track contract from the Spanish Ministry of Science and Innovation (RYC2020-029690-I).es_ES
dc.format.number1es_ES
dc.format.page44es_ES
dc.format.volume13es_ES
dc.identifier.citationCell Biosci. 2023 Mar 4;13(1):44.es_ES
dc.identifier.doi10.1186/s13578-023-00986-9es_ES
dc.identifier.issn2045-3701es_ES
dc.identifier.journalCell & biosciencees_ES
dc.identifier.pubmedID36871010es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16450
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC)es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-128106NA-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2021-031003-Ies_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2020-029690-Ies_ES
dc.relation.publisherversion10.1186/s13578-023-00986-9es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Mecanoadaptación y Biología de Caveolases_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleNanomedicine for autophagy modulation in cancer therapy: a clinical perspective.es_ES
dc.typereviewes_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication39ed17bc-9ad9-4e37-86b8-9a75e41c8856
relation.isAuthorOfPublication.latestForDiscovery39ed17bc-9ad9-4e37-86b8-9a75e41c8856

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Nanomedicine for autophagy_Cell Biosci_2023.pdf
Size:
1.17 MB
Format:
Adobe Portable Document Format
Description:
Review